Ref ID: 2746
Author:
J. STONE1, S. HOLLAND1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, R. MILLER1, A. FREEMAN1, S. DILZER2, K. LASSETER2
Author address:
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL.
Full conference title:
ICAAC 41st
Abstract:
Background: Caspofungin (CancidasTM, MK-0991, L-743,872) is a parenteral antifungal agent that inhibits the synthesis of 1,3 b-D glucan, an essential component of the fungal cell wall.
Methods: The potential for drug interactions between caspofungin and tacrolimus (FK-506) was evaluated in a placebo-controlled, randomized, Phase I study. Part (1) was a 2-period, parallel-panel study in which healthy subjects received tacrolimus (2 doses of 0.1 mg/kg oral capsules administered 12 hours apart, n=12) or placebo (n=5) alone in Period 1 and again on Day 10 of caspofungin 70 mg IV daily in Period 2. In Part (2), parallel panels of healthy subjects received tacrolimus (2 doses of 0.1 mg/kg 12 hours apart, n=8) or placebo (n=8) on Days 1 and 10 of caspofungin 50 mg IV daily.
Results: The geometric mean ratio (90% CI) for caspofungin plasma AUC(0-24hr) under coadministration relative to administration alone was 1.00 (0.96, 1.04) for Part (1) and 1.05 (0.96, 1.15) for Part (2), based on a mixed-model analysis that evaluated pharmacokinetic data obtained on Days 9 and 10 in both the coadministration and the placebo-control panels. The geometric mean ratio (90% CI) for tacrolimus whole blood AUC(0-12hr) in Period 2 (coadministration) relative to Period 1 (administration alone) was 0.80 (0.72, 0.89) for Part (1), based on a combined analysis of morning and evening doses. Reductions of similar magnitude were also seen for tacrolimus CMAX and C12hr. Conclusions: Tacrolimus does not alter the pharmacokinetics of caspofungin. Caspofungin modestly reduces whole blood concentrations of tacrolimus. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
Abstract Number: NULL
Conference Year: 2001
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Zaragoza R1, Pemán J2, Cantón E2, Camarena J1, Ayats J3, Torroba L4, Navarro D5, Royo G6, Echevarria J7,
Martinez J8, Guna R9, Ramirez I10, and the Spanish FUNGEMYCA group.2012
P823
n/a
-
v
P. Muñoz*, I. Cerón, M. Valerio, J. Palomo, A. Villa, A. Eworo,
J. Guinea, I.A. González, E. Bouza2012
P804
n/a
-
v
Pauline Krijgsheld,
A.F. Maarten Altelaar,
Harm Post,
Jeffrey H. Ringrose,
Wally H. Müller,
Albert J.R. Heck,
Han. A.B. Wösten2012
PR8.11
n/a
-
v
M. Nagao*, T. Saito, G. Hotta, S. Doi, M. Yamamoto, Y. Matsumura,
A. Matsushima, Y. Ito, S. Takakura, S. Ichiyama2012
NULL
n/a
-
v
R. Patel*, B. Saberwal, S. Quan, A. Gonzalez-Ruiz
2012
NULL
n/a
-
v
M.L. Moretti, P. Trabasso, L. Lyra, R. Fagnani, M.R. Resende,
L.F. Bachur, L.G.O. Cardoso*, A.Z. Schreiber2012
P783
n/a
-
v
C. Bulut*, Y. Kurtoglu Gul, C. Ataman Hatipoglu, S. Yagci,
A.P. Demiro¨2012
NULL
n/a
-
v
Sehnaz ALP, Sevtap ARIKAN-AKDAGLI, Dolunay GULMEZ, Sibel ASCIOGLU, Omrum UZUN, Murat AKOVA
2012
P777
n/a
-
v
S. Geith (1), F. Saghrouni (2), J. Ben Abdeljelil (2), I. khammari (2), W. Bannour (1), Y. Ben Youssef (3), S. Ben Salma (1), A. Khelif (3), M. Ben Said M (2), M. Njah (1), A. Fathallah (2).
2012
P775
n/a
-
v
E. Sala*, R. Mauri, S. Armitano, T. Tamborini, L. Villa, G. Tagliabue,
V. Caneva, D. Santoro, G. Giana2012
NULL
n/a